Quantcast

Industry news that matters to you.  Learn more

Great Point Partners Announces Sale of Caprion Proteomics

Great Point Partners, LLC recently announced the sale of Caprion Proteomics, Inc., a Great Point Partners I portfolio company. Caprion is a leading provider of proteomic services to the pharmaceutical industry that include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) in-vitro diagnostics development. Under Great Point’s investment, Caprion grew EBITDA by over 300x. The growth was primarily driven through strong organic growth, industry leadership and accretive tuck-in acquisitions.

Thirteen Proteomics Companies Form Proteomics Innovation Network

New England Peptide recently announced that it and twelve other product and service companies have started the global Proteomics Innovation Network to collaborate on unmet needs in drug discovery and personalized medicine.

The mission of the new proteomics network is to generate “from sample to discovery” solutions in all facets of proteomics, including expression, identification, characterization, interaction and function. Each member organization has complementary expertise, core technologies, and infrastructure to address critical unmet needs in biomarker and drug target discovery, personalized medicine, drug profiling, and selective reaction monitoring.